Cyclacel Pharmaceuticals - Stock Price History | CYCC

Historical daily share price chart and data for Cyclacel Pharmaceuticals since 2021 adjusted for splits. The latest closing stock price for Cyclacel Pharmaceuticals as of October 27, 2021 is 4.86.
  • The all-time high Cyclacel Pharmaceuticals stock closing price was 14953.50 on June 04, 2007.
  • The Cyclacel Pharmaceuticals 52-week high stock price is 11.42, which is 135% above the current share price.
  • The Cyclacel Pharmaceuticals 52-week low stock price is 3.16, which is 35% below the current share price.
  • The average Cyclacel Pharmaceuticals stock price for the last 52 weeks is 6.17.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Cyclacel Pharmaceuticals Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 6.4340 13.3840 18.3000 3.2100 7.8100 -41.72%
2019 12.1349 13.8600 20.0000 6.6900 13.4000 10.74%
2018 28.2184 35.2000 36.2000 11.2000 12.1000 -65.23%
2017 66.9788 109.4000 163.4000 31.8000 34.8000 -67.11%
2016 97.7719 117.6471 165.6000 65.0000 105.8000 -11.87%
2015 171.7213 168.0672 405.7623 115.7263 120.0480 -28.56%
2014 779.3184 1001.2005 1116.4466 163.2173 168.0432 -82.59%
2013 1000.9501 1440.5762 1440.5762 672.2689 965.1861 -33.66%
2012 1065.9967 942.9104 1822.3289 722.4723 1454.9820 46.78%
2011 1798.3427 2537.0540 2856.2860 655.2656 991.2992 -59.86%
2010 3214.0225 1747.3749 4973.2979 1696.9699 2469.8473 41.35%
2009 1285.8181 672.0673 2436.2439 428.4429 1747.3749 147.62%
2008 3704.2987 9039.3050 9039.3050 453.6454 705.6707 -92.34%
2007 11145.0331 11693.9708 14953.4971 8316.8327 9207.3218 -20.12%
2006 8386.0322 1176.1178 13810.9828 1125.7127 11525.9540 923.88%
2005 1566.6235 4771.6777 4771.6777 453.6454 1125.7127 -75.72%
2004 6506.2754 10265.8278 10736.2749 3360.3364 4637.2643 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.046B $0.000B
CYCLACEL is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine, a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and cutaneous T-cell lymphoma. Seliciclib (CYC202 or R-roscovitine), a CDK inhibitor, is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86